Apixaban formulations

A solid pharmaceutical composition comprising a therapeutically effective amount of apixaban and a pharmaceutically acceptable diluent or carrier,

• wherein raw materials from which the solid pharmaceutical composition is prepared comprise crystalline apixaban particles having a D90 equal to or less than about 89 μm, and
• wherein, as measured using a USP Apparatus 2 at a paddle rotation speed of 75 rpm in 900 mL of a dissolution medium at 37° C., at least 77 wt % of apixaban in the solid pharmaceutical composition dissolves within 30 minutes in the dissolution medium, and the dissolution medium is 0.05 M sodium phosphate at a pH 6.8 containing 0.05% sodium lauryl sulfate.

A tablet comprising from about 2.5 mg to about 5 mg of apixaban and a pharmaceutically acceptable diluent or carrier,

• wherein the tablet is prepared using crystalline apixaban particles having a D90 equal to or less than about 89 μm as a raw material, and
• wherein, as measured using a USP Apparatus 2 at a paddle rotation speed of 75 rpm in 900 mL of a dissolution medium at 37° C., at least 77 wt % of apixaban in the tablet dissolves within 30 minutes in the dissolution medium, and the dissolution medium is 0.05 M sodium phosphate at a pH 6.8 containing 0.05% sodium lauryl sulfate.

A capsule comprising from about 2.5 mg to about 5 mg of apixaban and a pharmaceutically acceptable diluent or carrier, wherein the capsule is prepared using crystalline apixaban particles having a D90 equal to or less than about 89 μm as a raw material, and wherein, as measured using a USP Apparatus 2 at a paddle rotation speed of 75 rpm in 900 mL of a dissolution medium at 37° C., at least 77 wt % of apixaban in the capsule dissolves within 30 minutes in the dissolution medium, and the dissolution medium is 0.05 M sodium phosphate at a pH 6.8 containing 0.05% sodium lauryl sulfate.